Moomoo AI 已提取核心訊息
On February 27, 2024, Allarity Therapeutics, Inc. entered into an amendment to their Senior Convertible Notes with 3i, LP. The amendment to the notes, originally dated January 18, 2024, and February 13, 2024, modifies Section 4(c)(vi) to prevent the Holder from converting the notes to common stock if such conversion would require stockholder approval or exceed 19.9% of the common stock shares. All other terms of the Notes remain unchanged. Additionally, on March 1, 2024, Allarity Therapeutics updated their corporate presentation slides and made them available on the company's website. These slides are intended for use in presentations to investors, analysts, and other interested parties. The information provided in the corporate presentation is furnished and not filed, nor is it incorporated by reference into any filing under the Securities Act or the Exchange Act.
On February 27, 2024, Allarity Therapeutics, Inc. entered into an amendment to their Senior Convertible Notes with 3i, LP. The amendment to the notes, originally dated January 18, 2024, and February 13, 2024, modifies Section 4(c)(vi) to prevent the Holder from converting the notes to common stock if such conversion would require stockholder approval or exceed 19.9% of the common stock shares. All other terms of the Notes remain unchanged. Additionally, on March 1, 2024, Allarity Therapeutics updated their corporate presentation slides and made them available on the company's website. These slides are intended for use in presentations to investors, analysts, and other interested parties. The information provided in the corporate presentation is furnished and not filed, nor is it incorporated by reference into any filing under the Securities Act or the Exchange Act.
2024年2月27日，Allarity Therapeutics, Inc.與3i, LP簽署了其優先可轉換票據的修正案。票據修正案最初於2024年1月18日和2024年2月13日發佈，對第4（c）（vi）條進行了修改，以防止持有人將票據轉換爲普通股，前提是這種轉換需要股東批准或超過普通股的19.9％。本票據的所有其他條款保持不變。此外，2024年3月1日，Allarity Therapeutics更新了他們的公司演示幻燈片，並將其發佈在公司的網站上。這些幻燈片旨在用於向投資者、分析師和其他有關各方進行演示。公司簡報中提供的信息是提供的，不是歸檔的，也沒有以引用方式納入根據《證券法》或《交易法》提交的任何文件中。
2024年2月27日，Allarity Therapeutics, Inc.與3i, LP簽署了其優先可轉換票據的修正案。票據修正案最初於2024年1月18日和2024年2月13日發佈，對第4（c）（vi）條進行了修改，以防止持有人將票據轉換爲普通股，前提是這種轉換需要股東批准或超過普通股的19.9％。本票據的所有其他條款保持不變。此外，2024年3月1日，Allarity Therapeutics更新了他們的公司演示幻燈片，並將其發佈在公司的網站上。這些幻燈片旨在用於向投資者、分析師和其他有關各方進行演示。公司簡報中提供的信息是提供的，不是歸檔的，也沒有以引用方式納入根據《證券法》或《交易法》提交的任何文件中。
有用
沒用